Neolabs Are Asked to Land Two Moonshots at Once. Pre-Registered Acquisitions Could Cut It to One
Put a price on breakthroughs
Neolabs are expected to deliver both a research breakthrough and a venture-scale business, two outcomes that are each roughly 1 in 100 on their own — together, 1 in 10,000. Borrowing from pharma, where small biotechs take on discovery risk and big companies buy the winners, the proposal is pre-registered acquisitions: frontier labs name a price and a target up front, committing to buy the first team that hits it. Labs keep scaling what works, researchers chase breakthroughs, and investors get a known buyer.
Put a price on the breakthrough and it only has to win one. The payoff is smaller than becoming the next Anthropic, but the odds go from 1 in 10,000 to 1 in 100, and that's a bet you can build a team around.